Arbre décisionnel du soin nutritionnel

Bouteloup, Corinne; Thibault, Ronan

doi:10.1016/j.nupar.2013.12.005

Cited by 29 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Demographic, biological and clinical data were collected at the time of blood collection for CDA activity assessment: sex, age, body mass index, active smoking, Eastern Cooperative Oncology Group performance status, malnutrition, inflammatory syndrome, liver disease, metastatic disease, liver metastasis, primary tumour location, haematological parameters, liver enzymes, total bilirubin, albumin, C‐reactive protein (CRP), ferritin, creatinine and planned chemotherapy. Malnutrition was defined according to the guidelines of the French Society of Clinical Nutrition and Metabolism (Supplemental Table S1) . Inflammatory syndrome was defined as increased levels of CRP, absolute neutrophil count or ferritin.…”

Section: Methodsmentioning

confidence: 99%

Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours

Cohen

Préta

Joste

et al. 2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

AIMSCytidine deaminase (CDA) activity in cancer patients' serum has been proposed as a predictive biomarker for efficacy and toxicity of nucleoside analogues. However, discrepant results about its predictive value have been reported due to the high interindividual variability in CDA activity. This study aimed at identifying determinants of this interindividual variability. METHODSFrom December 2014 to November 2015, 183 patients were prospectively included. Serum CDA activity, biological and clinical characteristics as well as five common single nucleotide polymorphisms (SNPs) in the CDA gene (c.-451C > T, c.-92A > G, c.-33_-31delC, c.79A > C, c.435 T > C) were analysed. Associations between clinical characteristics, pharmacogenetic variants and CDA activity were univariately tested. P < 0.1-candidate variables were analysed through a multivariate analysis. The association between CDA activity and toxicity was assessed for the 56 gemcitabine-treated patients. Intraindividual variability in CDA activity was explored in six pancreatic cancer patients treated with gemcitabine. RESULTSMedian CDA activity was 3.97 U mg -1 (range 1.53-15.49 U mg -1 ). A univariate analysis showed that CDA activity was statistically associated with Eastern Cooperative Oncology Group performance status, mild or severe malnutrition, inflammatory syndrome, leucocyte count, neutrophil count, albumin, C-reactive protein and -c.-33_-31delC single nucleotide polymorphism. A multivariate analysis identified that only neutrophil count (P < 0.0001) and severe malnutrition (P = 0.0278) were independently associated with CDA activity. Low CDA activity (<2 U mg -1 ) was not statistically associated with severe gemcitabine-related British Journal of Clinical Pharmacology Br toxicities (P = 0.16). A decrease in CDA activity was observed during the longitudinal follow-up of six pancreatic cancer patients treated with gemcitabine (P = 0.03). CONCLUSIONSThese results suggest that neutrophil count and malnutrition should be considered for the interpretation of pretherapeutic CDA activity. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Serum cytidine deaminase (CDA) activity in cancer patients is a potential biomarker for the efficacy and toxicity of nucleoside analogues. • Discrepant results have been reported due to the high interindividual variability of CDA activity. WHAT THIS STUDY ADDS• This study shows for the first time that elevated neutrophil count and malnutrition are significantly correlated with increased serum CDA activity in cancer patients. • Our work suggests that serum CDA activity should be interpreted along with the inflammation and malnutrition status. CDA serum activity in cancer patientsBr

show abstract

Section: Methodsmentioning

confidence: 99%

Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours

Cohen

Préta

Joste

et al. 2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Ces derniers peuvent être par exemple estimés par l'outil d'évaluation de la prise alimentaire (EPA ® ) permettant notamment au patient d'indiquer sur une échelle visuelle analogique ce qu'il mange actuellement entre « je ne mange rien » (0) et « je mange comme d'habitude » (10). Une EPA inférieure à 7/10 pose l'indication d'une intervention nutritionnelle [6].…”

Section: Facteurs De Risque Liés Au Patient (Comorbidités)unclassified

Traumatologie de la personne âgée : y a-t-il une place pour le support nutritionnel ?

Kouadio¹,

Biacchi²,

Zeanandin

et al. 2015

Nutrition Clinique et Métabolisme

Self Cite

View full text Add to dashboard Cite

“…• la prescription de CNO doit être précédée d'une évaluation de l'état nutritionnel du patient ainsi que d'une évaluation de ses ingesta et de ses besoins protéino-énergétiques [7][8][9] ; • les CNO sont indiqués pour tout patient non dénutri lorsque ses apports oraux sont inférieurs ou égaux à 20 kcal/kg par jour ou aux deux tiers des besoins ou lorsque l'échelle visuelle ou verbale alimentaire (EVA) est inférieure à 7, après échec ou plus souvent en association avec les conseils diététiques [2,7-9] ; • les CNO sont indiqués chez le patient modérément dénutri dont les apports oraux ne sont pas trop diminués (≥ 2/3 des besoins ou EVA ≥ 7) [2,7-9] ; • les CNO ne sont pas indiqués en première intention en cas d'apports oraux inférieurs ou égaux à deux tiers des besoins (ou EVA < 7) chez le patient dénutri, ou chez le patient sévè-rement dénutri quels que soient ses ingesta, ces situations devant faire discuter d'emblée la mise en place d'une nutrition entérale [2,[7][8][9] ; • les CNO sont contre-indiqués en cas de [3,8] :…”

Section: Sélection Des Items Parmi Les Textes De Référenceunclassified

“….) doivent être prises en compte pour la prescription de CNO [7][8][9] ; • la qualité de la prescription conditionne l'efficacité des CNO.…”

Section: Sélection Des Items Parmi Les Textes De Référenceunclassified

Référentiel de pratiques professionnelles : prescription et utilisation des compléments nutritionnels oraux chez l’adulte en milieu hospitalier

Guex¹,

Bouteloup

Bachmann³

et al. 2013

Nutrition Clinique et Métabolisme

Self Cite

View full text Add to dashboard Cite

show abstract

Arbre décisionnel du soin nutritionnel

Cited by 29 publications

References 9 publications

Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours

Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours

Traumatologie de la personne âgée : y a-t-il une place pour le support nutritionnel ?

Référentiel de pratiques professionnelles : prescription et utilisation des compléments nutritionnels oraux chez l’adulte en milieu hospitalier

Contact Info

Product

Resources

About